Tall cell percentage alone in PTC without aggressive features should not guide patients' clinical management.

Anello Marcello PomaDavid ViolaElisabetta MacerolaAgnese ProiettiEleonora MolinaroDario De VietroRossella EliseiGabriele MaterazziPaolo MiccoliFulvio BasoloClara Ugolini

Published in: The Journal of clinical endocrinology and metabolism (2021)

TCPTC and PTC with tall cell areas can be considered as a unique group with similar recurrence risk. However, whenever aggressive features are absent, tumors have a low risk of recurrence independently of tall cell percentage.

Keyphrases

single cell
cell therapy
end stage renal disease
newly diagnosed
peritoneal dialysis
free survival
patient reported outcomes